As megadeals continue to dominate headlines in 2015, there appears to be no end in sight for life sciences companies’ appetite for acquisitions. Almost all respondents in this survey, a remarkable 94%, are planning to make an acquisition over the next year. This should come as no surprise as the future success of many companies in the sector hinges on the ability to stay competitive and innovate by building new product pipelines that safeguard cash flows and avoid the risks of ground up development.

The complex anatomy of cross-border regulations involved in expanding the geographical reach of a product can be very demanding. Nevertheless, strategies that take into account technological breakthroughs can be even more difficult to identify and execute.

The influence of advances in genomics, for example, has yet to be fully explored, both in terms of opportunity and impact on an evolving regulatory landscape. Nevertheless, 70% of respondents in this survey show a strong interest in the personalised medicine segment of the life sciences sector.

Against this backdrop, Reed Smith surveyed the attitudes of leading life sciences businesses around the world about the realities of today’s marketplace.

This report explores the main drivers behind the avid pursuit for cross-border life sciences deals, the challenges faced in executing those deals, and how advances in personalised medicine may change the face of the industry.

Image title

Diane Frenier 
Reed Smith corporate partner, Princeton